Sight Sciences reports Q4 revenue $19.1M (+2% YoY); guides FY2025 revenue down 6%-12%

Sight Sciences, Inc.

Q4 total revenue $19.1M (+2% YoY); Surgical Glaucoma $18.8M (+9%), Dry Eye $0.3M (down from $1.6M).
FY2024 net loss $51.5M ($1.03/shr) vs $55.5M ($1.14/shr) prior; cash used $17.8M (62% improvement YoY).
FY2025 revenue guidance $70M-$75M (6%-12% decline) citing new Medicare LCDs restricting MIGS coverage with cataract.
Adj. operating expenses FY2025 guided $105M-$107M (+4-6%); next-gen OMNI expected H1 2025.
Gross margin Q4 87% vs 85% prior; cash and equivalents $120.4M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.